PAX1 hypomethylation as a prognostic biomarker for radioresistance of cervical cancer

Clinical Epigenetics

Table 1 Patients characteristics and the correlation between clinical variables and PAX1 gene methylation

Variables	N = 125	Hypomethylation (N = 15)	Hypermethylation (N = 110)	P
Age (year)	56.0 ± 9.0	57.8 ± 6.6	55.8 ± 9.2	0.415^a
FIGO stage				0.761^b
< IIB	10	2 (20.0%)	8 (80.0%)
≥ IIB	115	13 (11.3%)	102 (88.7%)
Pathology				0.152^c
SCC	119	13 (10.9%)	106 (89.1%)
AC	6	2 (33.3%)	4 (66.7%)
Lymph nodes				0.326^d
Negative	73	7 (9.6%)	66 (90.4%)
Positive	52	8 (15.4%)	44 (84.6%)
HPV16/18				0.049^*^d
Negative	39	8 (20.5%)	31 (79.5%)
Positive	86	7 (8.1%)	79 (91.9%)
Anemia				0.819^d
Yes	45	5 (11.1%)	40 (88.9%)
No	80	10 (12.5%)	70 (87.5%)
Tumor size (cm³)		19.0 ± 24.1	23.6 ± 25.3	0.508^a

HPV, Human papillomavirus; FIGO, International Federation of Gynecology and Obstetrics; SCC, squamous cell carcinoma; AC, adenocarcinoma
^at test
^bContinuous correction χ² test
^cFisher test
^dχ² test
^*Statistical significance

ISSN: 1868-7083